Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Masofaniten

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Essa drops lead cancer drug after falling short against Xtandi
    Essa drops lead cancer drug after falling short against Xtandi

    04 Nov 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/essa-abandons-sole-clinical-stage-drug-after-falling-short-against-xtandi

    FIERCE BIOTECH
    04 Nov 2024
    Share Share
    Essa Pharma Terminates Ph 2 Study of Masofaniten in Prostate Cancer
    Essa Pharma Terminates Ph 2 Study of Masofaniten in Prostate Cancer

    31 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined-with-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-302293568.html

    PR NEWSWIRE
    31 Oct 2024
    Share Share
    ESSA Pharma Reports Q3 2024 Financial Results And Updates
    ESSA Pharma Reports Q3 2024 Financial Results And Updates

    05 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-provides-corporate-update-and-reports-financial-results-for-fiscal-third-quarter-ended-june-30-2024-302213920.html

    PR NEWSWIRE
    05 Aug 2024
    Share Share
    ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
    ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data

    25 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-presents-updated-phase-1-masofaniten-epi-7386-clinical-data-at-the-2024-asco-genitourinary-cancers-symposium-302044194.html

    PR NEWSWIRE
    25 Jan 2024
    Share Share
    ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data
    ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data

    21 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-presents-updated-phase-1-masofaniten-epi-7386-clinical-data-at-the-european-society-of-medical-oncology-2023-congress-301963689.html

    PR NEWSWIRE
    21 Oct 2023
    Share Share
    ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten
    ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten

    18 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/essa-pharma-announces-initiation-of-phase-2-study-evaluating-masofaniten-epi-7386-in-combination-with-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-301929954.html

    PR NEWSWIRE
    18 Sep 2023
    Share Share